{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:12:23Z","timestamp":1793913143121,"version":"4.8.0"},"reference-count":147,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment armamentarium for a subset of patients with metastatic disease. Emerging data suggest that some ADCs exhibit impressive activity even in central nervous system (CNS) metastases, a disease site that is difficult to treat and associated with poor prognosis. Herein, we describe and summarize the existing evidence surrounding ADCs in NSCLC with a focus on CNS activity.<\/jats:p>","DOI":"10.3390\/curroncol31100471","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:53:43Z","timestamp":1729583623000},"page":"6314-6342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antibody\u2013Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases"],"prefix":"10.3390","volume":"31","author":[{"given":"David J. H.","family":"Bian","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara F.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Anatomy & Cell Biology, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-7159","authenticated-orcid":false,"given":"Anna-Maria","family":"Lazaratos","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Montreal. Montreal, QC H3A 1G1, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0811-876X","authenticated-orcid":false,"given":"Nathaniel","family":"Bouganim","sequence":"additional","affiliation":[{"name":"Department of Oncology, McGill University Health Centre, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-5895","authenticated-orcid":false,"given":"Matthew","family":"Dankner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"ref_1","unstructured":"(2024, September 01). Canadian Cancer Society. Cancer Statistics at a Glance. Cancer Statistics. Available online: https:\/\/cancer.ca\/en\/research\/cancer-statistics\/cancer-statistics-at-a-glance."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e230475","DOI":"10.1001\/jamanetworkopen.2023.0475","article-title":"Association of Brain Metastases with Survival in Patients with Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/PPO.0000000000000146","article-title":"Lung Cancer Brain Metastases","volume":"21","author":"Goldberg","year":"2015","journal-title":"Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dankner, M., Lam, S., Degenhard, T., Garzia, L., Guiot, M.C., Petrecca, K., and Siegel, P.M. (2021). The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers. Cancers, 13.","DOI":"10.3390\/cancers13040732"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1624","article-title":"The Evolving Modern Management of Brain Metastasis","volume":"25","author":"Fecci","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/jps.10424","article-title":"Blood-Brain Barrier Efflux Transport","volume":"92","author":"Golden","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e29668","DOI":"10.1016\/j.heliyon.2024.e29668","article-title":"Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis","volume":"10","author":"Bian","year":"2024","journal-title":"Heliyon"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"CT082","DOI":"10.1158\/1538-7445.AM2020-CT082","article-title":"Abstract CT082: Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)","volume":"80","author":"Garon","year":"2020","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.jtho.2018.12.027","article-title":"Response of BRAFV600E-Mutant Lung Adenocarcinoma with Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment","volume":"14","author":"Yamamoto","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"LBA9016","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9016","article-title":"Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)","volume":"41","author":"Dingemans","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"CT131","DOI":"10.1158\/1538-7445.AM2019-CT131","article-title":"Abstract CT131: Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)","volume":"79","author":"Doebele","year":"2019","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2019.37.15_suppl.2006","article-title":"Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors","volume":"37","author":"Drilon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved Overall Survival and Locoregional Disease Control with Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients with Brain Metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: Dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody\u2013drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14712598.2021.1880562","article-title":"What makes a good antibody-drug conjugate?","volume":"21","author":"Galbraith","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","article-title":"Drug conjugates for the treatment of lung cancer: From drug discovery to clinical practice","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/path.4583","article-title":"Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance","volume":"237","author":"Saunus","year":"2015","journal-title":"J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2603","article-title":"HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer","volume":"12","author":"Simpson","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.breast.2014.06.011","article-title":"Co-overexpression of HER2\/HER3 is a predictor of impaired survival in breast cancer patients","volume":"23","author":"Berghoff","year":"2014","journal-title":"Breast"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/apm.12063","article-title":"Frequent overexpression of ErbB\u2014Receptor family members in brain metastases of non-small cell lung cancer patients","volume":"121","author":"Berghoff","year":"2013","journal-title":"APMIS"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaal4682","DOI":"10.1126\/scitranslmed.aal4682","article-title":"The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation","volume":"9","author":"Kodack","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-23-0020","article-title":"Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer","volume":"29","author":"Tomasich","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/his.12475","article-title":"Amplification and overexpression of is a common event in brain metastases of non-small cell lung cancer","volume":"65","author":"Preusser","year":"2014","journal-title":"Histopathology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1158\/0008-5472.CAN-18-1102","article-title":"Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis","volume":"78","author":"Xing","year":"2018","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, Y., Smith, M.R., Wang, Y., D\u2019Agostino, R., Ruiz, J., Lycan, T., Kucera, G.L., Miller, L.D., Li, W., and Chan, M.D. (2023). c-Met Mediated Cytokine Network Promotes Brain Metastasis of Breast Cancer by Remodeling Neutrophil Activities. Cancers, 15.","DOI":"10.3390\/cancers15092626"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10585-013-9584-7","article-title":"Gene silencing of c-Met leads to brain metastasis inhibitory effects","volume":"30","author":"Lee","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2016","journal-title":"Protein Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ducry, L. (2013). Linker Technologies for Antibody\u2013Drug Conjugates. Antibody-Drug Conjugates, Humana Press.","DOI":"10.1007\/978-1-62703-541-5"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","article-title":"Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker","volume":"14","author":"Oflazoglu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Baah, S., Laws, M., and Rahman, K.M. (2021). Antibody\u2013Drug Conjugates\u2014A Tutorial Review. Molecules, 26.","DOI":"10.3390\/molecules26102943"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mckertish, C.M., and Kayser, V. (2021). Advances and Limitations of Antibody Drug Conjugates for Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080872"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody\u2013Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody\u2013drug conjugates: A new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Gogia, P., Ashraf, H., Bhasin, S., and Xu, Y. (2023). Antibody\u2013Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence. Cancers, 15.","DOI":"10.3390\/cancers15153886"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bartsch, R., Berghoff, A.S., Furtner, J., Marhold, M., Bergen, E.S., Roider-Schur, S., Mair, M.J., Starzer, A.M., Forstner, H., and Rottenmanner, B. (2024). Final outcome analysis from the phase II Tuxedo-1 Trial of Trastuzumab-Deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro-Oncol., noae123.","DOI":"10.1093\/neuonc\/noae123"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"TPS2091","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2091","article-title":"Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial","volume":"42","author":"Bartsch","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med."},{"key":"ref_61","first-page":"157","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial","volume":"25","author":"Cortez","year":"2022","journal-title":"Neuro-Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Vaz Batista, M., P\u00e9rez-Garc\u00eda, J.M., Garrig\u00f3s, L., Garc\u00eda-S\u00e1enz, J.\u00c1., Cortez, P., Racca, F., Blanch, S., Ruiz-Borrego, M., Fern\u00e1ndez-Ortega, A., and Fern\u00e1ndez-Abad, M. (2024). The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med.","DOI":"10.1016\/j.medj.2024.08.001"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Harbeck, N., Ciruelos, E., Jerusalem, G., M\u00fcller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M.J., and Connolly, R.M. (2024). Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b\/4 trial. Nat. Med.","DOI":"10.1038\/s41591-024-03261-7"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100395","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives","volume":"31","author":"Peters","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4143\/crt.2022.359","article-title":"Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing","volume":"55","author":"Ahn","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1245\/s10434-015-5044-8","article-title":"Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer","volume":"24","author":"Bu","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00432-022-04196-7","article-title":"Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations","volume":"149","author":"Zhuo","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Li, X., Zhao, C., Su, C., Ren, S., Chen, X., and Zhou, C. (2016). Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2875-z"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kim, E.K., Kim, K.A., Lee, C.Y., and Shim, H.S. (2017). The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171280"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_76","first-page":"3645","article-title":"HER-2\/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry1","volume":"9","author":"Pellegrini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_77","first-page":"5238","article-title":"HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of herceptin","volume":"9","author":"Gross","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4143\/crt.2019.186","article-title":"Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea","volume":"52","author":"Lee","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody\u2013Cytotoxic Drug Conjugate","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"102924","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.021","article-title":"Trastuzumab emtansine for patients with non\u2013small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations","volume":"162","author":"Iwama","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non\u2013Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers","volume":"25","author":"Peters","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non\u2013Small Cell Lung Cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_90","unstructured":"Phillips, C. (2024). FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer. Cancer Currents: An NCI Cancer Research Blog, National Cancer Institute."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor\u2013Resistant, EGFR-Mutated Non\u2013Small Cell Lung Cancer","volume":"12","author":"Baik","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.breast.2023.04.008","article-title":"Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases","volume":"69","author":"Lazaratos","year":"2023","journal-title":"Breast"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.21037\/jtd-20-3265","article-title":"A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers","volume":"13","author":"Wu","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: A multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in cancer: From the bench to the bedside","volume":"41","author":"Pandiella","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1158\/1078-0432.CCR-08-2921","article-title":"HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors","volume":"15","author":"Sun","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Scharpenseel, H., Hanssen, A., Loges, S., Mohme, M., Bernreuther, C., Peine, S., Lamszus, K., Goy, Y., Petersen, C., and Westphal, M. (2019). EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-43678-6"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A Novel HER3-Targeting Antibody\u2013Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3\u2013Directed Antibody-Drug Conjugate, in Patients with Previously Treated Human Epidermal Growth Factor Receptor 3\u2013Expressing Metastatic Breast Cancer: A Multicenter, Phase I\/II Trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: Phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pathol.2023.11.006","article-title":"Prognostic and predictive biomarkers in non-small cell lung carcinoma","volume":"56","author":"Odintsov","year":"2024","journal-title":"Pathology"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Len\u00e1rt, S., Len\u00e1rt, P., \u0160marda, J., Rem\u0161\u00edk, J., Sou\u010dek, K., and Bene\u0161, P. (2020). Trop2: Jack of All Trades, Master of None. Cancers, 12.","DOI":"10.3390\/cancers12113328"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2016.01.032","article-title":"TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells","volume":"470","author":"Li","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/1354750X.2016.1201532","article-title":"Clinical value of serum trophoblast cell surface protein 2 (TROP2) antibody in non-small-cell lung cancer patients","volume":"21","author":"Zheng","year":"2016","journal-title":"Biomarkers"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/ol.2013.1368","article-title":"Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma","volume":"6","author":"Jiang","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/pin.12911","article-title":"Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation","volume":"70","author":"Mito","year":"2020","journal-title":"Pathol. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1016\/j.annonc.2023.09.2450","article-title":"1419P TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases","volume":"34","author":"Moliner","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Mountzios","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: A phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., and P\u00e9rol, M. (2024). Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J. Clin. Oncol., JCO-24-01544.","DOI":"10.1016\/j.annonc.2023.10.588"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/fon-2023-0230","article-title":"TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC","volume":"19","author":"Levy","year":"2023","journal-title":"Future Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Yuan, X., Tian, Q., Huang, X., Chen, Y., Pu, Y., Long, H., Xu, M., Ji, Y., and Xie, J. (2022). Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.951589"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1200\/JCO.2023.41.16_suppl.9114","article-title":"SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study","volume":"41","author":"Fang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2024.42.16_suppl.8502","article-title":"Sacituzumab tirumotecan (SKB264\/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study","volume":"42","author":"Fang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.1996.646","article-title":"Overexpression and activation of hepatocyte growth factor\/scatter factor in human non-small-cell lung carcinomas","volume":"74","author":"Olivero","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1158\/0008-5472.CAN-15-3541","article-title":"Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer","volume":"76","author":"Xing","year":"2016","journal-title":"Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"100319","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Yang, M., Mandal, E., Liu, F.X., O\u2019Hara, R.M., Lesher, B., and Sanborn, R.E. (2024). Non-small cell lung cancer with MET amplification: Review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1241402"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oncolo\/oyac094","article-title":"Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases","volume":"27","author":"Huang","year":"2022","journal-title":"Oncologist"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","article-title":"MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes","volume":"24","author":"Mazieres","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_137","first-page":"197","article-title":"High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol. Histopathol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S799","DOI":"10.1016\/j.annonc.2023.09.2429","article-title":"1397P Prevalence, molecular characterization, and prognosis of MET-overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort","volume":"34","author":"Bar","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met Antibody\u2013Drug Conjugate that Targets Both MET\u2013Amplified and c-Met\u2013Overexpressing Tumors, Irrespective of MET Pathway Dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients with Previously Treated c-Met Protein\u2013Overexpressing Advanced Nonsquamous EGFR-Wildtype Non\u2013Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","article-title":"A Phase II Study of Telisotuzumab Vedotin in Patients with c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","volume":"22","author":"Waqar","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS Efficacy of Osimertinib with or Without Chemotherapy in Epidermal Growth Factor Receptor\u2013Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"42","author":"Planchard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"vdab188","DOI":"10.1093\/noajnl\/vdab188","article-title":"Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: An open-label, 3-arm, phase II pilot study","volume":"4","author":"Peled","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II Efficacy and Safety of 80 mg Osimertinib in Patients with Leptomeningeal Metastases Associated with Epidermal Growth Factor Receptor Mutation\u2013Positive Non\u2013Small Cell Lung Cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/10\/471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:16:28Z","timestamp":1760112988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/10\/471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":147,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["curroncol31100471"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31100471","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}